• Belite Bio scheduled oral presentation May 22, 2026 at Retina China 2026 covering previously disclosed topline results from Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1.
• Study readout showed tinlarebant slowed disease progression versus placebo, supporting clinical benefit in adolescent Stargardt patients.
• Safety profile was described as generally tolerable, consistent with drug mechanism.
• Belite Bio initiated rolling FDA submission in April 2026, positioning tinlarebant for potential US approval review in STGD1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.